CLINICAL EXPERIENCES OF LIVIDOMYCIN ON RESPIRATORY TRACT INFECTIONS

Clinical effects of a newly developed aminoglycoside antibiotic lividomycin, were investigated in 13 patients suffering from respiratory infections. 1. A total of 13 patients with the following infectious diseases was treated with 1 g/day of lividomycin for 3-11 days (average 6.7 days): Acute pneumo...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1975/04/25, Vol.28(2), pp.149-154
Main Authors: KONDO, HIROTUNE, MIWA, TARO, YOKOUCHI, SUHACHIRO, ANDO, YOSHITERU
Format: Article
Language:Japanese
Subjects:
Acute Disease
Adult
Aged
Bronchiectasis - drug therapy
Bronchitis - drug therapy
Drug Resistance, Microbial
Empyema - drug therapy
Female
Haemophilus - drug effects
Haemophilus - isolation & purification
Humans
Male
Middle Aged
Neisseria - drug effects
Neisseria - isolation & purification
Paromomycin - analogs & derivatives
Paromomycin - pharmacology
Pneumonia - drug therapy
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Staphylococcus - drug effects
Staphylococcus - isolation & purification
Streptococcus - drug effects
Streptococcus - isolation & purification
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical effects of a newly developed aminoglycoside antibiotic lividomycin, were investigated in 13 patients suffering from respiratory infections. 1. A total of 13 patients with the following infectious diseases was treated with 1 g/day of lividomycin for 3-11 days (average 6.7 days): Acute pneumonia 3 cases, bronchiectasis 3 cases, acute bronchitis 5 cases, suppurative diseases of the lung 1 case, and pyothorax 1 case. As the results, the antibiotic was effective in 5 patients, moderately effective in 4 patients and ineffective in 4 patients, and thus the global effective rate was 62.9% (9/13). 2. As in the case of kanamycin, lividomycin indicated fairly good sensitivity against a total of 17 strains comprising Staphylococcus aureus (7 strains), α-Streptococcus (2 strains), β-Streptococcus (3 strains), γ-Streptococcus (1 strain), Neisseria (2 strains) and Haemophilus (2 strains) which were isolated from sputum. 3. No side effects attributable to lividomycin were observed.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.28.149